Título: | PHOTOLUMINESCENT SEMICONDUCTORS NANOPARTICLES AS OPTICAL PROBES FOR THE DETERMINATION OF CAPTOPRIL, HISTAMINE, AMINOGLYCOSIDES AND THYROXINE | |||||||
Autor: |
SARZAMIN KHAN |
|||||||
Colaborador(es): |
RICARDO QUEIROZ AUCELIO - Orientador |
|||||||
Catalogação: | 20/DEZ/2021 | Língua(s): | ENGLISH - UNITED STATES |
|||||
Tipo: | TEXT | Subtipo: | THESIS | |||||
Notas: |
[pt] Todos os dados constantes dos documentos são de inteira responsabilidade de seus autores. Os dados utilizados nas descrições dos documentos estão em conformidade com os sistemas da administração da PUC-Rio. [en] All data contained in the documents are the sole responsibility of the authors. The data used in the descriptions of the documents are in conformity with the systems of the administration of PUC-Rio. |
|||||||
Referência(s): |
[pt] https://www.maxwell.vrac.puc-rio.br/projetosEspeciais/ETDs/consultas/conteudo.php?strSecao=resultado&nrSeq=56662&idi=1 [en] https://www.maxwell.vrac.puc-rio.br/projetosEspeciais/ETDs/consultas/conteudo.php?strSecao=resultado&nrSeq=56662&idi=2 |
|||||||
DOI: | https://doi.org/10.17771/PUCRio.acad.56662 | |||||||
Resumo: | ||||||||
Recently, semiconductor nanocrystals, also known as quantum dots, have
become very attractive for photoluminescence based sensing approaches due to
their unique optical properties like intense photoluminescence with narrow profile,
maximum wavelength adjustable by the control of particle size and higher
photostability in comparison of conventional organic dyes. Different synthesized
nanoparticles were evaluated as photoluminescent probes (as aqueous dispersions)
for the determination of captopril, histamine, kanamycin and thyroxine (nonphotoluminescent
analytes at room-temperature) avoiding the use of complex
chemical derivatization procedures and enabling simple and sensitive
quantifications. Thioglycolic acid (TGA) and 2-mercapoprionic acid (2MPA)
modified CdTe nanoparticles and L-cysteine modified ZnS nanoparticles were
synthesized via the colloid aqueous phase route. Their characterization was made
using proper microscopic and spectroscopic methods.
The emission intensity of 2MPA-Cdte is greatly enhanced in the presence
of captopril. Under optimum conditions, the calibration model (Langmuir binding
isotherm) was linear up to 4.8 x 10-4 mol L-1 with equilibrium binding constant of
3.2 x 104 L mol-1 and limit of detection (LOD) of 6.2 x 10-6 mol L-1 (1.3 (micro)g mL-1).
Applications in captopril fortified human serum and in pharmaceutical
formulations were demonstrated. The photoluminescence of TGA-CdTe
nanoparticles was quenched by histamine in a concentration dependent manner
(Stern-Volmer model). The linear response covered the concentration range up to
5.7 x 10-4 mol L-1 with LOD of 9.6 x 10-6 mol L-1 (1.1 (micro)g mL-1). The proposed
method was used for the analysis of tuna fish. The presence of aminoglycosides
enhanced the photoluminescence of the TGA-CdTe nanoparticles (following a
Langmuir binding isotherm model). Kanamycin was used as a model
aminoglycoside in order to study its effect on the photoluminescence enhancement
of TGA-CdTe quantum dots dispersed in aqueous solution. The linear range
extended up to 8.2 x 10-7 mol L-1 with LOD of 2.5 x 10-8 mol L-1 (14.2 ng mL-1).
Binding constants were calculated for several aminoglycosides indicating that
there is a relationship between the number of available primary amino groups and
the increasing in photoluminescence. This approach was successfully applied for
determination of kanamycin fortified milk and in stream water samples after solid
phase extraction using a molecular imprinted polymer produced using a
kanamycin template. The photoluminescence intensity of cysteine-ZnS in solution
containing cetyltrimethyl ammonium bromide (CTAB) was quenched by
thyroxine. The overall quenching followed a Stern-Volmer model with linear
response coveing an analyte concentration range up to 4.0 x 10-6 mol L-1. LOD
was 6.2 x 10-8 mol L-1 (48.3 ng mL-1). The aqueous dispersion of cysteine-ZnS
was used as optical probe for the determination of thyroxine in pharmaceutical
formulations and in analyte fortified human saliva.
|
||||||||